Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1

British Journal of Pharmacology

Volumn 153, Issue 6, 2008, Pages 1214-1224

  Murthy, K S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Muscle relaxation; Phosphodiesterases; Protein kinase G; Protein phosphatase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ACETYLCHOLINE; CYCLIC GMP; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; METHOCTRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OKADAIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHODIESTERASE V; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; S NITROSOGLUTATHIONE; TAUTOMYCIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HYDROLYSIS; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RABBIT;

ACETYLCHOLINE; ANIMALS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN PHOSPHATASE 1; RABBITS; RECEPTOR, MUSCARINIC M3; RHOA GTP-BINDING PROTEIN; S-NITROSOGLUTATHIONE; STOMACH;

EID: 40949135108     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707686     Document Type: Article

References (40)

1. Bender AT, Beavo JA (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
2. Bessay EP, Zoraghi R, Blount MA, Grimes KA, Beasley A, Francis SH et al. (2007). Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Front Biosci 12: 1899-1910.
3. Corbin JD, Turko IV, Beasley A, Francis SH (2000). Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267: 2760-2767.
4. Eto M, Karginov A, Brautigan DL (1999). A novel phosphoprotein inhibitor of protein type-1 phosphatase holoenzymes. Biochemistry 38: 16952-16957.
5. Eto M, Kitazawa T, Yazawa M, Mukai H, Ono Y, Brautigan DL (2001). Histamine-induced vasoconstriction involves phosphorylation of a specific inhibitor protein for myosin phosphatase by protein kinase C alpha and delta isoforms. J Biol Chem 276: 29072-29078.
6. Eto M, Ohmori T, Suzuki M, Furuya K, Morita F (1995). A novel protein phosphatase-1 inhibitory protein potentiated by protein kinase C. Isolation from porcine aorta media and characterization. J Biochem (Tokyo) 118: 1104-1107.
7. Francis SH, Corbin JD (2005). Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 1: 283-293.
8. Gopal VK, Francis SH, Corbin JD (2001). Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem 268: 3304-3312.
9. Kim D, Aizawa T, Wei H, Pi X, Rybalkin SD, Berk BC et al. (2005). Angiotensin II increases phosphodiesterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signaling. J Mol Cell Cardiol 38: 175-184.
10. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T et al. (2001). Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104: 2338-2343.
11. Koesling D, Mullershausen F, Lange A, Friebe A, Mergia E, Wagner C et al. (2005). Negative feedback in NO/cGMP signalling. Biochem Soc Trans 33: 1119-1122.
12. Liu QR, Zhang PW, Lin Z, Li QF, Woods AS, Troncoso J et al. (2004). GBPI, a novel gastrointestinal- and brain-specific PP1-inhibitory protein, is activated by PKC and inactivated by PKA. Biochem J 377: 171-181.
13. Liu QR, Zhang PW, Zhen Q, Walther D, Wang XB, Uhl GR (2002). KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine. J Biol Chem 277: 13312-13320.
14. Lochhead A, Nekrasova E, Arshavsky VY, Pyne NJ (1997). The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase. J Biol Chem 272: 18397-18403.
15. Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D, Friebe A (2001). Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155: 271-278.
16. Murthy KS (2001a). Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J 360: 199-208.
17. 2+ release by preferential activation of cGMP-primed PKG. Am J Physiol Gastrointest Liver Physiol 281: G1238-G1245.
18. Murthy KS (2004). Modulation of soluble guanylate cyclase activity by phosphorylation. Neurochem Int 45: 845-851.
19. Murthy KS (2006). Signaling for contraction and relaxation in smooth muscle of the gut. Annu Rev Physiol 68: 345-374.
20. Murthy KS, Makhlouf GM (1995a). Agonist-mediated activation of phosphatidylcholine-specific phospholipase C and D in intestinal smooth muscle. Mol Pharmacol 48: 293-304.
21. Murthy KS, Makhlouf GM (1995b). Interaction of cA-kinase and cG-kinase in mediating relaxation of dispersed smooth muscle cells. Am J Physiol 268: C171-C180.
22. 2+ mobilization by cyclic nucleotides in isolated gastric muscle cells. Am J Physiol 264: G967-G974.
23. 3R-I in vivo by cGMP-dependent protein kinase in smooth muscle. Am J Physiol Gastrointest Liver Physiol 284: G221-G230.
24. Murthy KS, Zhou H, Grider JR, Brautigan DL, Eto M, Makhlouf GM (2003a). Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway. Biochem J 374: 145-155.
25. Murthy KS, Zhou H, Grider JR, Makhlouf GM (2001). Sequential activation of heterotrimeric and monomeric G proteins mediates PLD activity in smooth muscle. Am J Physiol Gastrointest Liver Physiol 280: G381-G388.
26. Murthy KS, Zhou H, Grider JR, Makhlouf GM (2003b). Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am J Physiol Gastrointest Liver Physiol 284: G1006-G1016.
27. Murthy KS, Zhou H, Makhlouf GM (2002). PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. Am J Physiol Cell Physiol 282: C508-C517.
28. Pyne NJ, Arshavsky V, Lochhead A (1996). cGMP signal termination. Biochem Soc Trans 24: 1019-1022.
29. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003a). PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22: 469-478.
30. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003b). Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93: 280-291.
31. Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, Feil R, Wolfsgruber W, Hofmann F et al. (2003). Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 23: 6452-6459.
32. Soderling SH, Beavo JA (2000). Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12: 174-179.
33. Somlyo AP, Somlyo AV (2004). Signal transduction through the RhoA/Rho-kinase pathway in smooth muscle. J Muscle Res Cell Motil 25: 613-615.
34. Turko IV, Francis SH, Corbin JD (1998). Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J 329: 505-510.
35. Uji A, Matsuda M, Kukita T, Maeda K, Kanematsu T, Hirata M (2002). Molecules interacting with PRIP-2, a novel Ins(1,4,5)P3 binding protein type 2: Comparison with PRIP-1. Life Sci 72: 443-453.
36. Wyatt TA, Naftilan AJ, Francis SH, Corbin JD (1998). ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol 274: H448-H455.
37. Yanagihori S, Terunuma M, Koyano K, Kanematsu T, Ho Ryu S, Hirata M (2006). Protein phosphatase regulation by PRIP, a PLC-related catalytically inactive protein - implications in the phospho-modulation of the GABAA receptor. Adv Enzyme Regul 46: 203-222.
38. Zhou H, Das S, Murthy KS (2003). Erk1/2- and p38 MAP kinase-dependent phosphorylation and activation of cPLA2 by m3 and m2 receptors. Am J Physiol Gastrointest Liver Physiol 284: G472-G480.
39. Zhou H, Murthy KS (2004). Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2. Am J Physiol Cell Physiol 286: C1130-C1138.
40. Zoraghi R, Bessay EP, Corbin JD, Francis SH (2005). Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280: 12051-12063.